-
Something wrong with this record ?
Methotrexate released in vitro from bone cement inhibits human stem cell proliferation in S/G2 phase
E. Procházka, T. Soukup, M. Hroch, L. Fuksa, E. Brčáková, J. Cermanová, G. Kolouchová, K. Urban, J. Mokrý, S. Mičuda
Language English Country Germany
Document type Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1997 to 2014-03-31
PubMed Central
from 1997 to 2014
Europe PubMed Central
from 1997 to 2014
Medline Complete (EBSCOhost)
from 2007-02-01 to 1 year ago
- MeSH
- Bone Marrow Cells pathology drug effects MeSH
- Interphase drug effects MeSH
- Bone Cements chemistry MeSH
- Cells, Cultured MeSH
- Humans MeSH
- Methotrexate administration & dosage chemistry MeSH
- Mesenchymal Stem Cells pathology drug effects MeSH
- Cell Proliferation drug effects MeSH
- Antimetabolites, Antineoplastic administration & dosage chemistry MeSH
- Cell Survival drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
Methotrexate (MTX) released from bone cement showed a useful local effect in animal models of bone tumours. However, local toxic reactions such as impaired wound healing were observed in areas surrounding the MTX-loaded implant. Therefore, we hypothesised that MTX released from bone cement would have harmful effects on human mesenchymal stem cells (MSC)-one of the basic components of bone marrow and tissue reparatory processes. Moreover, elution of MTX was calculated from implants prepared either with liquid or powdered MTX. During the 28-day incubation, the cement compounded with liquid MTX showed the highest elution rate of the drug. MTX released from pellets produced a significant decrease in proliferation of MSC as a consequence of a blockade of their cell cycle in the S/G2 phase. These findings indicate impairment of stem cell function in marginal areas surrounding the MTX-loaded cement and may help to explain problems with regeneration of tissues in these locations.
- 000
- 02907naa a2200481 a 4500
- 001
- bmc12008642
- 003
- CZ-PrNML
- 005
- 20130129164337.0
- 008
- 120316s2010 gw eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $d ABA008
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Procházka, Egon $7 xx0070634 $u Department of Orthopedic Surgery, Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
- 245 10
- $a Methotrexate released in vitro from bone cement inhibits human stem cell proliferation in S/G2 phase $c E. Procházka, T. Soukup, M. Hroch, L. Fuksa, E. Brčáková, J. Cermanová, G. Kolouchová, K. Urban, J. Mokrý, S. Mičuda
- 520 9_
- $a Methotrexate (MTX) released from bone cement showed a useful local effect in animal models of bone tumours. However, local toxic reactions such as impaired wound healing were observed in areas surrounding the MTX-loaded implant. Therefore, we hypothesised that MTX released from bone cement would have harmful effects on human mesenchymal stem cells (MSC)-one of the basic components of bone marrow and tissue reparatory processes. Moreover, elution of MTX was calculated from implants prepared either with liquid or powdered MTX. During the 28-day incubation, the cement compounded with liquid MTX showed the highest elution rate of the drug. MTX released from pellets produced a significant decrease in proliferation of MSC as a consequence of a blockade of their cell cycle in the S/G2 phase. These findings indicate impairment of stem cell function in marginal areas surrounding the MTX-loaded cement and may help to explain problems with regeneration of tissues in these locations.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a protinádorové antimetabolity $x aplikace a dávkování $x chemie $7 D000964
- 650 02
- $a kostní cementy $x chemie $7 D001843
- 650 02
- $a buňky kostní dřeně $x patologie $x účinky léků $7 D001854
- 650 02
- $a proliferace buněk $x účinky léků $7 D049109
- 650 02
- $a viabilita buněk $x účinky léků $7 D002470
- 650 02
- $a kultivované buňky $7 D002478
- 650 02
- $a lidé $7 D006801
- 650 02
- $a interfáze $x účinky léků $7 D007399
- 650 02
- $a mezenchymální kmenové buňky $x patologie $x účinky léků $7 D059630
- 650 02
- $a methotrexát $x aplikace a dávkování $x chemie $7 D008727
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Soukup, Tomáš, $d 1980- $7 xx0036274
- 700 1_
- $a Hroch, Miloš, $d 1976- $7 xx0076212
- 700 1_
- $a Fuksa, Leoš. $7 _BN001818
- 700 1_
- $a Doleželová, Eva. $7 xx0179807
- 700 1_
- $a Cermanová, Jolana, $d 1965- $7 xx0076211
- 700 1_
- $a Kolouchová, Gabriela. $7 _BN005219
- 700 1_
- $a Urban, Karel, $d 1943- $7 skuk0005685
- 700 1_
- $a Mokrý, Jaroslav, $d 1964- $7 jn20000620235
- 700 1_
- $a Mičuda, Stanislav, $d 1972- $7 jn20010309083
- 773 0_
- $t International Orthopaedics $p Int Orthop $g Roč. 34, č. 1 (2010), s. 137-142 $w MED00002384 $x 0946-1965
- 773 0_
- $p Int Orthop $g 34(1):137-42, 2010 Feb
- 910 __
- $a ABA008 $b x $y 4
- 990 __
- $a 20120319124601 $b ABA008
- 991 __
- $a 20121031151923 $b ABA008
- 999 __
- $a ok $b bmc $g 901987 $s 765537
- BAS __
- $a 3
- BMC __
- $a 2010 $b 34 $c 1 $d 137-142 $m International orthopaedics $x MED00002384
- LZP __
- $a 2012-1Q10/
